Pfizer - Steady Annual Performance Despite Disturbances: ICICI Direct
The Pfizer Inc. logo is seen on the lab coat of an employee at the company’s research and development facility in Cambridge. (Photographer: Scott Eisen/Bloomberg).

Pfizer - Steady Annual Performance Despite Disturbances: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Pfizer Ltd.'s FY21 revenues grew 4.0% YoY to Rs 2,239 crore with hospital and vaccines business impacted amid the pandemic.

Ebitda margins expanded 520 basis points to 31.8% YoY due to a better overall operational performance.

Decline in other expenses is likely on account of lower promotional and marketing activities related expenses.

Ebitda grew 24.4% YoY to Rs 712 crore. However, profit after tax de-grew 2.3% YoY to Rs 498 crore.

Delta vis-a-vis Ebitda was due to lower other income and tax reversals in the base year.

Click on the attachment to read the full report:

ICICI Direct Pfizer Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.